BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians’ recommendations

References

• Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130.
   PubMed Web of Science ®Google Scholar
• Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77–102.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–1622.
   PubMed Web of Science ®Google Scholar
• Finch APM, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–1553.
   PubMed Web of Science ®Google Scholar
• Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol. 2009;113(5):1027–1037.
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–828.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kuhle CL, Shuster LT, et al. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015;18(4):483–491.
   PubMed Web of Science ®Google Scholar
• Hickey M, Moss KM, Mishra GD, et al. What Happens After Menopause? (WHAM): a prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol. 2021;162(1):88–96.
   PubMed Web of Science ®Google Scholar
• Gordhandas S, Norquist BM, Pennington KP, et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol. 2019;153(1):192–200.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24:728–753.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Banks E, Beral V, Bull D, et al. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427.
   PubMed Web of Science ®Google Scholar
• Huber D, Seitz S, Kast K, et al. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol. 2021;147(7):2035–2045.
   PubMed Web of Science ®Google Scholar
• Vermeulen RFM, Korse CM, Kenter GG, et al. Safety of hormone replacement therapy following risk-reducing salpingooophorectomy: systematic review of literature and guidelines. Climacteric. 2019;22(4):352–360.
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Gronwald J, Karlan BY, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059–1065.
   PubMed Web of Science ®Google Scholar
• Michaelson-Cohen R, Gabizon-Peretz S, Armon S, et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer. 2021;148:95–102.
   PubMed Web of Science ®Google Scholar
• Gaba F, Manchanda R. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract Res Clin Obstet Gynaecol. 2020;65:46–65.
   PubMed Web of Science ®Google Scholar
• Cohen JV, Chiel L, Boghossian L, et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer. 2012;11(1):69–75.
   PubMed Web of Science ®Google Scholar
• Segerer R, Peschel C, Kämmerer U, et al. Factors impacting on decision-making towards prophylactic surgeries in BRCA mutation carriers and women with familial predisposition. Breast Care (Basel). 2020;15(3):253–259.
   PubMed Web of Science ®Google Scholar
• Flippo-Morton T, Walsh K, Chambers K, et al. Surgical decision making in the BRCA-positive population: institutional experience and comparison with recent literature. Breast J. 2016;22(1):35–44.
   PubMed Web of Science ®Google Scholar
• Grandi G, Sola VB, Cortesi L, et al. BRCA mutation carriers’ perceptions on postmenopausal hormone therapy: an Italian study. Psychooncology. 2021;30(10):1711–1719.
   PubMed Web of Science ®Google Scholar
• Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012; 8(3):144–148.
   PubMedGoogle Scholar
• Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996;24(3):161–175. https://pubmed.ncbi.nlm.nih.gov/8844630/
   PubMed Web of Science ®Google Scholar
• Siyam T, Ross S, Shandro T, et al. Perspectives and decision-making about menopausal therapies in women who had bilateral oophorectomy. Menopause. 2018;25(7):795–802.
   PubMed Web of Science ®Google Scholar
• Siyam T, Carbon J, Ross S, et al. Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): a narrative review. Maturitas. 2019;120:68–76.
   PubMed Web of Science ®Google Scholar
• Miron-Shatz T, Konheim-Kalkstein YL. Preparedness and support, not personality, predict satisfaction in unplanned caesarean births. J Obstet Gynaecol. 2020;40(2):171–175.
   PubMedGoogle Scholar
• Madalinska JB, Van Beurden M, Bleiker EMA, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol. 2007;25(3):301–307.
   PubMed Web of Science ®Google Scholar
• Levy BT, Ritchie JM, Smith E, et al. Physician specialty is significantly associated with hormone replacement therapy use. Obstet Gynecol. 2003;101(1):114–122.
   PubMed Web of Science ®Google Scholar
• Lobb EA, Butow PN, Barratt A, et al. Communication and information-giving in high-risk breast cancer consultations: influence on patient outcomes. Br J Cancer. 2004;90(2):321–327.
   PubMed Web of Science ®Google Scholar
• Siyam T, Ross S, Campbell S, et al. The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. BMC Womens Health. 2017;17(1):1–13.
   PubMedGoogle Scholar